Referral Guidelines for Hematologic Conditions

Urgent Referral Indications

Patients with newly diagnosed immune thrombocytopenia (ITP) and platelet counts <20 × 10^9/L should be referred to a hematologist within 24-72 hours of diagnosis, regardless of whether they are managed as inpatients or outpatients, as recommended by the American Society of Hematology 1
Established ITP patients with platelet count <20 × 10^9/L need prompt hematology follow-up, according to the American Society of Hematology 1
Patients with hematologic malignancies, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic myeloid leukemia (CML) resistant to or intolerant of TKIs, should be referred to a hematologist, as recommended by the National Comprehensive Cancer Network 2

ITP patients who are corticosteroid-dependent or unresponsive to corticosteroids after ≥3 months should be referred to a hematologist, according to the American Society of Hematology 3
Patients with suspected myelodysplastic syndromes (MDS) or myeloproliferative neoplasms should be referred to a hematologist, as recommended by the National Comprehensive Cancer Network 2
Patients with multiple myeloma, particularly those with high-risk cytogenetic changes, should be referred to a hematologist, according to the International Myeloma Society 2

Elderly patients (>60 years) with thrombocytopenia may require more aggressive management due to higher bleeding risk, as recommended by the American Geriatrics Society 3
Patients on anticoagulant or antiplatelet medications with thrombocytopenia have increased bleeding risk and need specialized management, according to the American Heart Association 3

Adults with newly diagnosed ITP and platelet count <20 × 10^9/L who are asymptomatic or have minor mucocutaneous bleeding should be admitted rather than managed as outpatients, as recommended by the American Society of Hematology 1
Adults with established ITP and platelet count <20 × 10^9/L who are asymptomatic or have minor mucocutaneous bleeding can be managed as outpatients with expedited hematology follow-up, according to the American Society of Hematology 1

Failing to ensure timely follow-up with a hematologist within 24-72 hours for urgent conditions, as recommended by the American Society of Hematology 1

Unexplained cytopenias in any cell line should prompt referral to a hematologist, according to the American Society of Hematology 4
Abnormal peripheral blood smear showing immature myeloid cells or dysplastic features should prompt referral to a hematologist, as recommended by the College of American Pathologists 4

The American Society of Hematology recommends that patients with critically low WBC counts should not wait one month for a hematologist appointment, even if asymptomatic, due to the risk of rapid clinical deterioration or underlying serious pathology such as acute leukemia, myelodysplastic syndromes, or bone marrow failure syndromes 5, 6.

Patients with critically low WBC counts, such as those with severe neutropenia, require expedited hematology consultation within 24-72 hours, similar to the management approach for severe thrombocytopenia, to assess for underlying conditions like acute leukemia (AML, ALL) or myelodysplastic syndromes 5, 6.
The presence of severe drug-induced agranulocytosis, such as with clozapine, requires immediate intervention and hematology consultation within 24 hours 7.

A WBC count <2,000/mm³ or absolute neutrophil count (ANC) <1,000/mm³ represents severe risk requiring immediate action in certain contexts, such as clozapine monitoring, and warrants prompt hematology referral 7.

For asymptomatic patients with critically low WBC, immediate actions (same day) should include repeat CBC with manual differential, review peripheral smear for abnormal cells, assess medication history, and check for infection signs 5, 8.
Hematology consultation should occur within 24-72 hours, and if initial repeat CBC shows worsening or persistent abnormality, bone marrow examination should be performed within 2-4 weeks 5, 8.

Higher-risk features requiring even more urgent evaluation (within 24 hours) include progressive decline in WBC over serial measurements, multiple cytopenias present simultaneously, abnormal peripheral smear showing blasts or dysplastic features, recent chemotherapy or immunosuppressive medication exposure, and history of autoimmune disease or prior hematologic abnormalities 5, 8.

While awaiting urgent hematology consultation, patients should be educated about infection warning signs (fever, chills, sore throat) requiring emergency evaluation, and potentially myelosuppressive medications should be reviewed and discontinued if safe to do so 7, 8.
Invasive procedures should be avoided until hematologic status is clarified, and empiric growth factor support should only be considered after hematology consultation to avoid obscuring underlying diagnosis 5, 6.